Login
$HUMA
$0.53 -$0.03 (4.66%) Live

$HUMA SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption

07 Oct 2026 Form 4: Coward D Scott, Director

Granted 125,000 Stock Options (right to buy)

07 Oct 2026 Form 4: Kuznik Paul Brian, Director

Granted 125,000 Stock Options (right to buy)

28 Sep 2026 Form 3: Kuznik Paul Brian, Director

Holds 65,719 shares of Common Stock

28 Sep 2026 Form 3: Coward D Scott, Director

No securities owned

28 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik

15 Sep 2026 Form 4: Jones Keith Anthony, Director

Bought 10,000 shares ($5.62K)

25 Aug 2026 25-NSE
21 Aug 2026 Form 4: Jones Keith Anthony, Director

Bought 10,000 shares ($6.93K)

19 Aug 2026 Form 4: Jones Keith Anthony, Director

Bought 30,000 shares ($17.8K)

18 Aug 2026 SCHEDULE 13D/A
12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition

– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA...

31 Jul 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On July 31, 2026, Humacyte, Inc. (the “Company”) received a letter from the staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid pric...

28 Jul 2026 SCHEDULE 13G/A
13 Jul 2026 SCHEDULE 13D/A
22 Jun 2026 SCHEDULE 13G
15 Jun 2026 SCHEDULE 13D/A
12 Jun 2026 Form 4: Wallace Max N., Director

Granted 80,000 Stock Options (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support